guest ::
| Home > Publications Database > Amyloid-PET imaging predicts functional decline in clinically normal individuals. > print |
| Home > Publications Database > Amyloid-PET imaging predicts functional decline in clinically normal individuals. > print |
| 001 | 270307 | ||
| 005 | 20240809090117.0 | ||
| 024 | 7 | _ | |a pmc:PMC11181677 |2 pmc |
| 024 | 7 | _ | |a 10.1186/s13195-024-01494-9 |2 doi |
| 024 | 7 | _ | |a pmid:38886831 |2 pmid |
| 024 | 7 | _ | |a altmetric:164630913 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-00779 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Quenon, Lisa |b 0 |
| 245 | _ | _ | |a Amyloid-PET imaging predicts functional decline in clinically normal individuals. |
| 260 | _ | _ | |a London |c 2024 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1719823393_19446 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a There is good evidence that elevated amyloid-β (Aβ) positron emission tomography (PET) signal is associated with cognitive decline in clinically normal (CN) individuals. However, it is less well established whether there is an association between the Aβ burden and decline in daily living activities in this population. Moreover, Aβ-PET Centiloids (CL) thresholds that can optimally predict functional decline have not yet been established.Cross-sectional and longitudinal analyses over a mean three-year timeframe were performed on the European amyloid-PET imaging AMYPAD-PNHS dataset that phenotypes 1260 individuals, including 1032 CN individuals and 228 participants with questionable functional impairment. Amyloid-PET was assessed continuously on the Centiloid (CL) scale and using Aβ groups (CL < 12 = Aβ-, 12 ≤ CL ≤ 50 = Aβ-intermediate/Aβ± , CL > 50 = Aβ+). Functional abilities were longitudinally assessed using the Clinical Dementia Rating (Global-CDR, CDR-SOB) and the Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q). The Global-CDR was available for the 1260 participants at baseline, while baseline CDR-SOB and A-IADL-Q scores and longitudinal functional data were available for different subsamples that had similar characteristics to those of the entire sample.Participants included 765 Aβ- (61%, Mdnage = 66.0, IQRage = 61.0-71.0; 59% women), 301 Aβ± (24%; Mdnage = 69.0, IQRage = 64.0-75.0; 53% women) and 194 Aβ+ individuals (15%, Mdnage = 73.0, IQRage = 68.0-78.0; 53% women). Cross-sectionally, CL values were associated with CDR outcomes. Longitudinally, baseline CL values predicted prospective changes in the CDR-SOB (bCL*Time = 0.001/CL/year, 95% CI [0.0005,0.0024], p = .003) and A-IADL-Q (bCL*Time = -0.010/CL/year, 95% CI [-0.016,-0.004], p = .002) scores in initially CN participants. Increased clinical progression (Global-CDR > 0) was mainly observed in Aβ+ CN individuals (HRAβ+ vs Aβ- = 2.55, 95% CI [1.16,5.60], p = .020). Optimal thresholds for predicting decline were found at 41 CL using the CDR-SOB (bAβ+ vs Aβ- = 0.137/year, 95% CI [0.069,0.206], p < .001) and 28 CL using the A-IADL-Q (bAβ+ vs Aβ- = -0.693/year, 95% CI [-1.179,-0.208], p = .005).Amyloid-PET quantification supports the identification of CN individuals at risk of functional decline.The AMYPAD PNHS is registered at www.clinicaltrialsregister.eu with the EudraCT Number: 2018-002277-22. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Amyloid-PET |2 Other |
| 650 | _ | 7 | |a Centiloid |2 Other |
| 650 | _ | 7 | |a Functional decline |2 Other |
| 650 | _ | 7 | |a Instrumental activities of daily living |2 Other |
| 650 | _ | 7 | |a Preclinical Alzheimer |2 Other |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Positron-Emission Tomography: methods |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Cross-Sectional Studies |2 MeSH |
| 650 | _ | 2 | |a Longitudinal Studies |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides: metabolism |2 MeSH |
| 650 | _ | 2 | |a Activities of Daily Living |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: metabolism |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Brain: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Brain: metabolism |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 700 | 1 | _ | |a Collij, Lyduine E |b 1 |
| 700 | 1 | _ | |a Garcia, David Vállez |b 2 |
| 700 | 1 | _ | |a Lopes Alves, Isadora |b 3 |
| 700 | 1 | _ | |a Gérard, Thomas |b 4 |
| 700 | 1 | _ | |a Malotaux, Vincent |b 5 |
| 700 | 1 | _ | |a Huyghe, Lara |b 6 |
| 700 | 1 | _ | |a Gispert, Juan Domingo |b 7 |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-2719)2000032 |b 8 |u dzne |
| 700 | 1 | _ | |a Visser, Pieter Jelle |b 9 |
| 700 | 1 | _ | |a den Braber, Anouk |b 10 |
| 700 | 1 | _ | |a Ritchie, Craig W |b 11 |
| 700 | 1 | _ | |a Boada, Mercè |b 12 |
| 700 | 1 | _ | |a Marquié, Marta |b 13 |
| 700 | 1 | _ | |a Vandenberghe, Rik |b 14 |
| 700 | 1 | _ | |a Luckett, Emma S |b 15 |
| 700 | 1 | _ | |a Schöll, Michael |b 16 |
| 700 | 1 | _ | |a Frisoni, Giovanni B |b 17 |
| 700 | 1 | _ | |a Buckley, Christopher |b 18 |
| 700 | 1 | _ | |a Stephens, Andrew |b 19 |
| 700 | 1 | _ | |a Altomare, Daniele |b 20 |
| 700 | 1 | _ | |a Ford, Lisa |b 21 |
| 700 | 1 | _ | |a Birck, Cindy |b 22 |
| 700 | 1 | _ | |a Mett, Anja |b 23 |
| 700 | 1 | _ | |a Gismondi, Rossella |b 24 |
| 700 | 1 | _ | |a Wolz, Robin |b 25 |
| 700 | 1 | _ | |a Grootoonk, Sylke |b 26 |
| 700 | 1 | _ | |a Manber, Richard |b 27 |
| 700 | 1 | _ | |a Shekari, Mahnaz |b 28 |
| 700 | 1 | _ | |a Lhommel, Renaud |b 29 |
| 700 | 1 | _ | |a Dricot, Laurence |b 30 |
| 700 | 1 | _ | |a Ivanoiu, Adrian |b 31 |
| 700 | 1 | _ | |a Farrar, Gill |b 32 |
| 700 | 1 | _ | |a Barkhof, Frederik |b 33 |
| 700 | 1 | _ | |a Hanseeuw, Bernard J |b 34 |
| 700 | 1 | _ | |a Consortium, AMYPAD |b 35 |e Collaboration Author |
| 773 | _ | _ | |a 10.1186/s13195-024-01494-9 |g Vol. 16, no. 1, p. 130 |0 PERI:(DE-600)2506521-X |n 1 |p 130 |t Alzheimer's research & therapy |v 16 |y 2024 |x 1758-9193 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP1.docx |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP2.docx |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP1.doc |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP1.odt |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP1.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP2.doc |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP2.odt |
| 856 | 4 | _ | |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779%20SUP2.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/270307/files/DZNE-2024-00779.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:270307 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2000032 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-19 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-19 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS RES THER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T15:09:21Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T15:09:21Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-19 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-19 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-19 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-19 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ALZHEIMERS RES THER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2023-04-12T15:09:21Z |
| 920 | 1 | _ | |0 I:(DE-2719)1011102 |k AG Jessen |l Clinical Alzheimer’s Disease Research |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1011102 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|